1. Home
  2. WNW vs ARTL Comparison

WNW vs ARTL Comparison

Compare WNW & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

HOLD

Current Price

$4.64

Market Cap

4.3M

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.46

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNW
ARTL
Founded
2015
2011
Country
China
United States
Employees
N/A
7
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
WNW
ARTL
Price
$4.64
$1.46
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
2.3M
177.2K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.94
52 Week High
$13.52
$28.60

Technical Indicators

Market Signals
Indicator
WNW
ARTL
Relative Strength Index (RSI) 61.31 27.25
Support Level $1.37 $1.08
Resistance Level $5.56 $1.50
Average True Range (ATR) 0.76 0.24
MACD 0.01 -0.10
Stochastic Oscillator 58.51 9.06

Price Performance

Historical Comparison
WNW
ARTL

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: